These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 25744459)

  • 1. Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylenation.
    Takahiro R; Nakamura S; Kohno H; Yoshimura N; Nakamura T; Ozawa S; Hirono K; Ichida F; Taguchi M
    Biol Pharm Bull; 2015; 38(1):58-65. PubMed ID: 25744459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil.
    Ku HY; Ahn HJ; Seo KA; Kim H; Oh M; Bae SK; Shin JG; Shon JH; Liu KH
    Drug Metab Dispos; 2008 Jun; 36(6):986-90. PubMed ID: 18308836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets.
    Bajraktari G; Burhenne J; Bugert P; Haefeli WE; Weiss J
    Biochem Pharmacol; 2017 Dec; 145():54-63. PubMed ID: 28964803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol.
    Hiratsuka M; Hinai Y; Sasaki T; Konno Y; Imagawa K; Ishikawa M; Mizugaki M
    Drug Metab Dispos; 2007 Oct; 35(10):1730-2. PubMed ID: 17646278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
    Williams JA; Ring BJ; Cantrell VE; Jones DR; Eckstein J; Ruterbories K; Hamman MA; Hall SD; Wrighton SA
    Drug Metab Dispos; 2002 Aug; 30(8):883-91. PubMed ID: 12124305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites.
    Botsch S; Gautier JC; Beaune P; Eichelbaum M; Kroemer HK
    Mol Pharmacol; 1993 Jan; 43(1):120-6. PubMed ID: 8423765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A.
    Liu KH; Kim MG; Lee DJ; Yoon YJ; Kim MJ; Shon JH; Choi CS; Choi YK; Desta Z; Shin JG
    Drug Metab Dispos; 2006 Nov; 34(11):1793-7. PubMed ID: 16896065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of benidipine and its enantiomers' metabolism by human liver cytochrome P450 enzymes.
    Yoon YJ; Kim KB; Kim H; Seo KA; Kim HS; Cha IJ; Kim EY; Liu KH; Shin JG
    Drug Metab Dispos; 2007 Sep; 35(9):1518-24. PubMed ID: 17537876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Maternal and Fetal CYP3A-Mediated Progesterone Metabolism.
    Quinney SK; Benjamin T; Zheng X; Patil AS
    Fetal Pediatr Pathol; 2017 Oct; 36(5):400-411. PubMed ID: 28949811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus.
    Kamdem LK; Streit F; Zanger UM; Brockmöller J; Oellerich M; Armstrong VW; Wojnowski L
    Clin Chem; 2005 Aug; 51(8):1374-81. PubMed ID: 15951320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the CYP3A Selective Inhibitors CYP3cide, Clobetasol, and Azamulin for Their Potential to Distinguish CYP3A7 Activity in the Presence of CYP3A4/5.
    Work HM; Kandel SE; Lampe JN
    Drug Metab Dispos; 2024 Oct; 52(11):1224-1233. PubMed ID: 38702193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver.
    Jacobsen W; Kirchner G; Hallensleben K; Mancinelli L; Deters M; Hackbarth I; Benet LZ; Sewing KF; Christians U
    Drug Metab Dispos; 1999 Feb; 27(2):173-9. PubMed ID: 9929499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of CYP3A activity endogenous markers for evaluating drug-drug interaction between sildenafil and CYP3A inhibitors in healthy subjects.
    Lee S; Kim AH; Yoon S; Lee J; Lee Y; Ji SC; Yoon SH; Lee S; Yu KS; Jang IJ; Cho JY
    Drug Metab Pharmacokinet; 2021 Feb; 36():100368. PubMed ID: 33348240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.
    Desta Z; Soukhova N; Mahal SK; Flockhart DA
    Drug Metab Dispos; 2000 Jul; 28(7):789-800. PubMed ID: 10859153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms.
    Pearce RE; Gotschall RR; Kearns GL; Leeder JS
    Drug Metab Dispos; 2001 Dec; 29(12):1548-54. PubMed ID: 11717173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide).
    Tseng E; Walsky RL; Luzietti RA; Harris JJ; Kosa RE; Goosen TC; Zientek MA; Obach RS
    Drug Metab Dispos; 2014 Jul; 42(7):1163-73. PubMed ID: 24737844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes.
    Zhu M; Zhao W; Jimenez H; Zhang D; Yeola S; Dai R; Vachharajani N; Mitroka J
    Drug Metab Dispos; 2005 Apr; 33(4):500-7. PubMed ID: 15640381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relative contributions of CYP3A4 and CYP3A5 to the metabolism of vinorelbine.
    Topletz AR; Dennison JB; Barbuch RJ; Hadden CE; Hall SD; Renbarger JL
    Drug Metab Dispos; 2013 Sep; 41(9):1651-61. PubMed ID: 23780963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism.
    Tang PF; Zheng X; Hu XX; Yang CC; Chen Z; Qian JC; Cai JP; Hu GX
    Drug Des Devel Ther; 2020; 14():5129-5141. PubMed ID: 33262574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes.
    Klees TM; Sheffels P; Dale O; Kharasch ED
    Drug Metab Dispos; 2005 Mar; 33(3):303-11. PubMed ID: 15557344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.